Locate Therapeutics Successfully Achieves ISO 13845 Certification for Design, Development and Control of Manufacture for Resorbable Biomaterials
Proprietary matrix TAOS® offers multiple benefits in delivery of advanced therapeutics for regenerative medicine applications
23 Jan 2018
Locate Therapeutics, a leading UK regenerative medicine company has announced that it has successfully achieved EN ISO 13845:2016 certification for the design control and control of manufacturing of resorbable injectable tissue scaffolds for use in bone repair and regeneration.
Currently Locate is developing a pipeline of combination therapies using its patented TAOS® polymer-based matrix as a delivery system. The latest of these, CellFuse, is a potentially breakthrough personalised cell therapy aimed at spinal fusion patients with compromised cell populations. Combining TAOS with another proprietary technology IntraStem, the CellFuse project also recenlty received a Biomedical Catalyst award.
“We are delighted to have received this certification which recognises the hard work and dedication of our team,” commented Dr Helen Cox, Quality Systems Manager. “In 2018 we expect to achieve multiple milestones across our portfolio resulting in new generation therapies for difficult to treat conditions” added CEO Robin Quirk.